Your session is about to expire
← Back to Search
Biospecimen Collection for Peritoneal Cancer
N/A
Recruiting
Led By Maheswari Senthil, MD FACS
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is researching the causes of gastrointestinal cancer. Patients provide blood, tumor samples, and fluids for study.
Who is the study for?
This trial is for adults over 18 with peritoneal carcinomatosis originating from gastrointestinal tumors, who are scheduled for standard surgical procedures. They must be able to understand and sign consent forms. Those unable to follow the study protocol cannot participate.
What is being tested?
The study involves collecting biospecimens such as blood, ascites/peritoneal wash fluid, and tumor samples during planned surgeries of patients with gastrointestinal peritoneal carcinomatosis.
What are the potential side effects?
Since this trial focuses on sample collection rather than drug testing, there are no direct side effects related to medications. However, typical risks associated with surgical procedures may apply.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT)
Establishment of angioarchitechture of peritoneal lesions through Optical Coherence Tomography Angiography (OCTA)
Secondary study objectives
Compare response of therapeutic regimens in a pdPC VMT to the observed clinical response (by RECIST criteria or diagnostic laparoscopy)
Overall Survival (OS)
Progression-Free Survival (PFS) at 6 months
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Subjects with Gastrointestinal Primary Tumor with or without Peritoneal CarcinomatosisExperimental Treatment1 Intervention
Subjects with gastrointestinal (GI) primary tumor with or without peritoneal carcinomatosis who are undergoing planned standard of care (SOC) surgical procedures. Biospecimens such as blood, peritoneal wash fluid and tumor samples will be obtained.
Find a Location
Who is running the clinical trial?
University of California, IrvineLead Sponsor
566 Previous Clinical Trials
1,933,028 Total Patients Enrolled
Maheswari Senthil, MD FACSPrincipal InvestigatorChao Family Comprehensive Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer started in the GI tract and has spread to the lining of my abdomen.I am scheduled for a standard surgery recommended for my condition.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.